Apimeds Pharmaceuticals US, Inc. (NYSEAM: APUS)
Health Care · Biotechnology · US
$4.97
+9.23% today · -79.3% 1Y
Apimeds Pharmaceuticals US, Inc. (NYSEAM: APUS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $6.87M and employs 7 people.
Over the last twelve months the share price has lost 79.3%, trading between 4.15 and 59.70.
APUS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $6.87M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- —
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $59.70
- 52-week low
- $4.15
- Avg volume (3M)
- —
- Shares outstanding
- 1.51M
- Employees
- 7
- Next earnings
- —
About Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. (APUS) functions as a clinical-stage biopharmaceutical firm operating within the United States. This company is dedicated to the entire lifecycle of its flagship product, Apitox – from its initial investigation and development to its production, market introduction, and sales. Apitox, a key active pharmaceutical ingredient, is specifically designed to alleviate inflammation and manage pain symptoms experienced by individuals suffering from osteoarthritis and multiple sclerosis. Established in 2020, APUS has its corporate headquarters situated in Hopewell, New Jersey, and operates as a subsidiary of Api Meds, Inc.
- ISIN
- US03771D2018
- Founded
- 2020
- Listed since
- May 9, 2025
- Exchange
- NYSE American LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $261.53 | -1.60% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $440.95 | -0.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $147.78 | -0.67% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $548.74 | -0.74% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $827.02 | -0.78% |
| argenx SEENXTBR: ARGX | $64.17B | €895.40 | +1.84% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $155.61 | -2.03% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.